Rhodie Smith and Todd Hudnall will be representing RxStrategies during the 2016 OACHC Fall Operations Conference from September 26-28, in Columbus, Ohio. Ready to connect with a 340B expert? We look forward to meeting with you! Contact us to learn more.
-
-
RxStrategies Helps to Celebrate KAMU 25th Year!
Join Todd Hudnall and the RxStrategies team as they attend the 2016 KAMU Annual Conference in Wichita, Kansas, September 21-23. This year will also mark KAMU’s 25th Anniversary! Congratulations to 25 years of success and your efforts to continuously improve access to health care in Kansas. We look forward to meeting with you! Contact us to… Read more »
-
Proud to Support APHCA as a Platinum Presenting Sponsor
Chief Operating Officer Tim Vroman and the RxStrategies team are pleased to network and connect with industry leaders during the APHCA Annual Conference in Mobile, Alabama, from September 20-22. We are especially proud to support the efforts of APHCA to strengthen health center network and improved access to primary care and coordinated services in communities… Read more »
-
Clinical Insights — August 2016 Issue
Welcome to the August edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approvals Adlyxin™ (lixisenatide) – July 28, 2016 – The U.S. Food and Drug Administration approved Adlyxin™ (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with… Read more »
-
Let’s Meet During NACHC 2016 CHI & eXpo
Chief Revenue Officer Skip Devanny and the RxStrategies team will be meeting with Health Center leaders Aug. 28 – 30, during the 2016 Community Health Institute (CHI) & eXpo in Chicago. Learn more about the NACHC 2016 Community Health Institute here. Ready to connect with a 340B expert? We look forward to meeting with… Read more »
-
Celebrating America’s Health Centers
National Health Center Week has been celebrated for more than 30 years to recognize the services and contributions of Community Health Centers. While there are countless reasons to celebrate America’s Health Centers, among the most important and unique is their long success in providing access to affordable, high quality, cost effective health care to medically… Read more »
-
Join RxStrategies at the FACHC 2016 Annual Meeting
Fenton Markevich and the RxStrategies team will be meeting with industry leaders during Florida Association of Community Health Centers 2016 Annual Meeting and Educational Summit.This year’s conference will take place July 31 – August 3, in Fort Lauderdale. Learn more about the conference here. We are looking forward to discussing integrated 340B program management solutions… Read more »
-
340B INSIDER – July 2016
Welcome to the July edition of RxStrategies 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view. UPDATES FROM THE 340B COALITION SUMMER CONFERENCE CONFERENCE HIGHLIGHTS RxStrategies’ Increased Presence at 340B Coalition Summer Conference It was great to connect with so many industry leaders during the conference. Thank you… Read more »
-
Adventist Health and RxStrategies, Inc. Agree to Extend its 340B Management Agreement
Adventist Health and RxStrategies, Inc. have agreed to continue the 340B program management agreement for an additional three years, the companies announced today. The agreement covers all of the participating sites for Adventist Health in the western states of California, Hawaii, Oregon and Washington. The agreement continues the relationship first established in 2012 between the… Read more »
-
Clinical Insights — April 2016 Issue
Welcome to the April edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Venclexta™ (venetoclax) April 11, 2016 – The U.S. Food and Drug Administration approved Venclexta™ (venetoclax) for the treatment of patients with chronic lymphocytic leukemia (CLL) who… Read more »